Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Adverse Drug Reactions in Children With Congenital Heart Disease: A Scoping Review Publisher Pubmed



Toni E1 ; Ayatollahi H2 ; Abbaszadeh R3 ; Fotuhi Siahpirani A4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Medical Informatics, Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Medical Informatics, Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Pediatric Cardiology, Heart Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran

Source: Pediatric Drugs Published:2024


Abstract

Background: Congenital heart disease (CHD) is one of the leading causes of death. Safe and timely medical interventions, especially in children, can prolong their survival. The drugs prescribed for children with CHD are mainly based on the outcomes of drug therapy in adults with cardiovascular diseases, and their adverse drug reactions (ADRs) might be different. Therefore, the aim of this study was to investigate ADRs in children with CHD. Methods: This was a scoping review conducted in 2023. PubMed, Web of Science, Scopus, the Cochrane Library, Ovid, ProQuest, and Google Scholar databases were searched. All studies that reported ADRs for children with CHD and were published in English by 1 November 2023 were included in this study. Finally, the results were reported using a content analysis method. Results: A total of 87 articles were included in the study. The results showed that symptoms/signs/clinical findings, and cardiovascular disorders were the most common ADRs reported in children with CHD. The results also showed that most of the ADRs were reported for prostaglandin E1, amiodarone, prostaglandin E2, dexmedetomidine, and captopril, respectively. Conclusion: The review underscores the wide array of ADRs in children with CHD, particularly in antiarrhythmics, diuretics, beta-blockers, anticoagulants, and vasodilators, which affected cardiovascular, respiratory, endocrine, metabolic, genitourinary, gastrointestinal, and musculoskeletal systems. Tailored treatment is imperative, considering individual patient characteristics, especially in the vulnerable groups. Further research is essential for optimizing dosing, pharmacogenetics, and alternative therapies to enhance patient outcomes in CHD management. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
Related Docs
1. Drug-Related Side Effects and Contributing Risk Factors in Children With Congenital Heart Disease: A Cross-Sectional Study, Health Science Reports (2025)
2. Cardiovascular Pharmacology in Pediatric Patients With Congenital Heart Disease, Congenital Heart Disease in Pediatric and Adult Patients: Anesthetic and Perioperative Management# Second Edition (2023)
Experts (# of related papers)
Samira Rajaei (1)